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Abstract: 
Omeprazole fast disintegrating tablets were prepared by using different superdisintegrants like crospovidone, 
croscarmellose sodium and Sodium starch glycolate by direct compression. Precompression parameters were 
conducted for all formulations blend and were found to be satisfactory. The prepared tablets were evaluated for 
various parameters like content uniformity, hardness, friability, wetting time, water absorption ratio, disintegration 
time and In-vitro dissolution. The results indicated that the tablets complied with the official specifications. The 
disintegration studies shown that the all formulations disintegrated in less than 1 minute. The formulation F3 shown 
less disintegration time of 15 seconds. The croscarmellose sodium and  sodium starch glycolate shown more 
disintegration time than crospovidone. In the present study, three Superdisintegrants representing each of the three 
main classes of superdisintegrants differed in their ability to disintegrate model tablet into their primary particles 
when used at the same w/w percentage concentration.  
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The Center for Drug Evaluation and Research 
(CDER), US FDA defined Oral Disintegrating 
Tablets (ODT) as “A solid dosage form containing 
medicinal substances, which disintegrates rapidly, 
usually within a matter of seconds, when placed upon 
the tongue.”   
A fast disintegrating or dissolving system or tablet 
can be defined as a solid dosage form that can 
disintegrate or dissolve within 30 seconds, in the oral 
cavity resulting in a solution or suspension without 
administration of water.  The fast disintegrating 
tablets are synonymous with fast dissolving tablets; 
melt in mouth tablets, rapimelts, Porous tablets, 





Omeprazole, Mannitol, Micro crystalline cellulose, 
Crospovidone, croscarmellose sodium, Sodium starch 
glycolate, Aspartame, Flavors, Magnesium stearate, 
Talc all the chemicals used were lab grade 
The basic approach used to study and evaluation of 
Fast disintegration tablet. For this study different 
superdisintegrants like crospovidone, croscarmellose 
and sodium starch glycolate were selected to 
formulate the Fast disintegrating tablets of 
Omeprazole by direct compression technique. 
             






F1 F2 F3 F4 F5 F6 F7 F8 F9 
Omeprazole 20 20 20 20 20 20 20 20 20 
MCC 201 197 193 201 197 193 201 197 193 
Crospovidone 4 8 12 - - - - - - 
Croscarmellose 
sodium - - - 4 8 12 - - - 
Sodium starch 
glycolate - - - - - - 4 8 12 
Mannitol 
10 10 10 10 10 10 10 10 10 
Aspartame 5 5 5 5 5 5 5 5 5 
Magnesium 
stearate 5 5 5 5 5 5 5 5 5 
Talc 
5 5 5 5 5 5 5 5 5 
Flavour qs qs qs qs qs qs qs qs qs 
Total 
250 250 250 250 250 250 250 250 250 
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Weight variation, Thickness, Hardness, Friability, 
Wetting time, Water absorption ratio, Content 
uniformity, In-vitro disintegration time,In-vitro 
release studies  are the evaluation tests performed for 
the prepared tablets. 
RESULTS AND DISCUSSION: 
Table 2: Standard graph for Omeprazole 
 
 
Fig 1: Standard graph Omeprazole 
Preformulation studies 
Table 3:  Preformulation studies of  API 
no Preformulation studies Omeprazole 
1 Bulk density (gm/ml) 0.47 
2 Tapped density (gm/ml) 0.54 
3 Angle of repose 21.2 
4 Carrs index 14.9 




S. No Concentration  (µ/ml) Absorbance (302 nm) 
1 0 0 
2 2 0.113 
3 4 0.253 
4 6 0.338 
5 8 0.469 
6 10 0.578 
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F1 0.40 0.47 21.5 14.8 1.17 
F2 0.41 0.46 20.1 10.86 1.12 
F3 0.41 0.47 19.6 12.7 1.14 
F4 0.43 0.48 17.8 10.4 1.11 
F5 0.41 0.45 19.2 8.88 1.09 
F6 0.40 0.44 18.4 9.09 1.10 
F7 0.44 0.50 18.5 12.0 1.13 
F8 0.41 0.46 17.4 10.86 1.12 
F9 0.42 0.48 17.8 12.5 1.14 
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Drug release study by in-vitro drug dissolution  
Table 6: Cumulative percentage drug release of CP & CCS and formulations. 
Sno Time 
Cumulative percentage of drug release of formulation 
F1 F2 F3 F4 F5 F6 
1 0 0 0 0 0 0 0 
2 1 22.38±0.730 25.85±1.000 28.09±0.844 17.54±0.965 18.13±1.395 21.64±0.837 
3 2 28.67±0.605 38.30±0.861 46.23±0.984 20.23± 0.962 25.34±0.968 29.83± 0.949 
4 3 34.39±0.628 43.73±0.888 57.85±0.717 25.88±0.895 31.85±0.835 36.79± 1.25 
5 4 42.82±0.850 51.51±0.846 68.53±0.977 31.45± 0.879 39.04±1.368 43.30± 1.67 
6 5 48.86±0.554 61.24±0.865 77.89±1.059 42.50± 1.248 45.95±1.354 51.83± 1.68 
7 6 56.21±0.743 66.87±0.725 87.24±1.064 48.65± 1.365 52.34±0.865 60.38± 1.396 
8 7 58.56±0.820 75.50±1.672 91.41±0.767 53.81± 1.845 60.41±0.849 69.69± 1.311 
9 8 67.80±0.921 78.07±0.791 96.36±0.750 60.79± 1.568 66.25±0.759 73.47± 1.386 
0 9 73.59±0.811 84.03±0.853 97.42±1.021 69.87± 1.648 74.81±0.839 85.13± 1.568 
11 10 86.42±0.637 93.25±0.782 99.29±0.410 76.16± 1.349 81.71±1.125 92.36± 1.649 
 
Table 7:  Cumulative percentage drug release of SSG formulations. 
Sno Time 
Cumulative percentage of drug release of formulation 
F7 F8 F9 
1 0 0 0 0 
2 1 
14.32±0.917 16.94±1.023 18.46± 1.026 
3 2 
18.54± 0.934 20.03± 1.325 23.23± 1.132 
4 3 
22.98± 0.934 26.53± 1.068 27.50± 1.165 
5 4 
29.53± 0.987 32.80± 1.235 32.01± 1.421 
6 5 
33.91± 0.865 39.62± 1.481 46.92± 1.134 
7 6 
41.77± 0.935 46.15± 1.368 53.08± 1.128 
8 7 
50.16± 0.948 53.79± 1.248 59.24± 1.169 
9 8 
54.51± 0.978 61.72± 1.168 66.27± 1.187 
10 9 
61.48± 0.967 69.79± 1.125 79.50± 1.194 
11 10 
71.55± 0.932 73.64± 1.091 86.35± 1.178 
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Table 8: Comparison F3, F6, F9 formulations. 
 
           
 





Fig 2: Cumulative percentage drug release of CP & CCS  formulations 
 
 






Fig 3: Cumulative percentage drug release of SSG formulations. 
 
S.No Time 
Cumulative percentage of drug release of formulation 
F3 F6 F9 
1 0 0 0 0 
2 1 28.09±0.844 21.64±0.837 18.46± 1.026 
3 2 46.23±0.984 29.83± 0.949 23.23± 1.132 
4 3 57.85±0.717 36.79± 1.25 27.50± 1.165 
5 4 68.53±0.977 43.30± 1.67 32.01± 1.421 
6 5 77.89±1.059 51.83± 1.68 46.92± 1.134 
7 6 87.24±1.064 60.38± 1.396 53.08± 1.128 
8 7 91.41±0.767 69.69± 1.311 59.24± 1.169 
9 8 96.36±0.750 73.47± 1.386 66.27± 1.187 
10 9 97.42±1.021 85.13± 1.568 79.50± 1.194 
11 10 99.29±0.410 92.36± 1.649 86.35± 1.178 
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Fig 4: Comparison F3, F6, F9 formulations 
 
SUMMARY AND CONCLUSION: 
Fast disintegrating tablets of Omeprazole were 
prepared by using different superdisintegrants like 
crospovidone, croscarmellose sodium and Sodium 
starch glycolate by direct compression. 
Precompression parameters were conducted for all 
formulations blend and were found to be satisfactory.  
The prepared tablets were evaluated for various 
parameters like content uniformity, hardness, 
friability, wetting time, water absorption ratio, 
disintegration time and In-vitro dissolution. The 
results indicated that the tablets complied with the 
official specifications. The disintegration studies 
shown that the all formulations disintegrated in less 
than 1 minute. The formulation F3 shown less 
disintegration time of 15 seconds. The croscarmellose 
sodium and sodium starch glycolate shown more 
disintegration time than crospovidone. In the present 
study, three Superdisintegrants representing each of 
the three main classes of superdisintegrants differed 
in their ability to disintegrate model tablet into their 
primary particles when used at the same w/w 
percentage concentration. In conclusion, it can be 
stated that the objective of the study has been 
achieved. From the above study the formula used for 
F3 formulation was concluded as an optimized 
formulation due to its less disintegration time and 
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